NRG-HN014:Randomized Phase III Trial Of Neoadjuvant Immunotherapy With Response-Adapted Treatment Versus Standard-Of-Care Treatment For Resectable Stage Iii/Iv Cutaneous Squamous Cell Carcinoma
Objective
To determine if neoadjuvant immunotherapy combined with response-adapted oncologic surgery improves site-reported event-free survival (EFS) compared to standard-of-care surgery in resectable stage III/IV CSCC.
To compare disease-free survival (DFS) between arms. To compare overall survival (OS) between arms. To compare adverse events (CTCAE v5.0) between arms. To assess pathologic complete response in Arm 2.
